NCT05007613 - Second-line Cabozantinib and Atezolizumab in Patients With Recurrent or Metastatic Esophageal Squamous Cell Carcinoma | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

June 23, 2021

Primary Completion Date

July 17, 2024

Study Completion Date

December 1, 2024

Conditions

Esophageal CancerMetastatic CancerSquamous Cell Carcinoma

Interventions

DRUG

Cabozantinib 40 MG

Cabozantinib (Cabometyx) 40 MG PO QD

DRUG

Atezolizumab Injection

atezolizumab (Tecentriq) 1200mg IVF 30-60mins Q3W

Trial Locations (1)

National Taiwan University Hospital, Taipei